NuCana (NASDAQ:NCNA) Downgraded to Market Perform at William Blair

William Blair downgraded shares of NuCana (NASDAQ:NCNA) from an outperform rating to a market perform rating in a report released on Friday morning, MarketBeat reports.

Separately, Oppenheimer reiterated an outperform rating and set a $150.00 price objective on shares of NuCana in a research report on Monday, August 19th.

NuCana Trading Down 52.7 %

Shares of NCNA opened at $3.66 on Friday. The business’s 50 day moving average is $4.06 and its 200 day moving average is $5.01. NuCana has a 12-month low of $2.53 and a 12-month high of $20.25. The company has a market capitalization of $9.67 million, a PE ratio of -0.31 and a beta of 0.99.

Institutional Investors Weigh In On NuCana

An institutional investor recently bought a new position in NuCana stock. Glass Jacobson Investment Advisors llc acquired a new position in shares of NuCana plc (NASDAQ:NCNA) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned approximately 0.57% of NuCana at the end of the most recent reporting period. 44.00% of the stock is currently owned by hedge funds and other institutional investors.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.